This $1,640,000.00 federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research by The University of Texas Southwestern Medical Center in Dallas, Texas to study the therapeutic parameters and mechanism of action of anti-miR-17 drugs in Autosomal Dominant Polycystic Kidney Disease (ADPKD). The 4-year award, running from April 1, 2025 to March 31, 2029, will enable UT Southwestern to conduct innovative scientific investigations, ranging from basic laboratory research to advanced clinical trials, to develop improved treatments for this chronic kidney condition affecting military personnel and the general public. As a leading academic medical center, UT Southwestern has extensive experience managing federal grants from agencies like the NIH across various disease areas, positioning it well to execute the research objectives of this Defense Health Agency award.
Generated 2/25/25, 3:58 AM